Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-24-014914

CHIEF FINANCIAL OFFICER sold 4,250 shares at an average $23.18 ($98,530)

  • CHIEF FINANCIAL OFFICER acquired 4,250 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Hohl Benjamin · CHIEF FINANCIAL OFFICER

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2024-05-28 Exercise or conversion : show line 1 in the form 10b5-1 +4,250 $2.48 $10,540 4,250 D
2024-05-28 Sale : show line 2 in the form 10b5-1 −1,906 $22.89 $43,628 2,344 D
2024-05-28 Sale : show line 3 in the form 10b5-1 −2,334 $23.42 $54,659 10 D
2024-05-28 Sale : show line 4 in the form 10b5-1 −10 $24.34 $243 0 D
Open-market sales · 4,250 sh · avg $23.18 · $98,530

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2024-05-28 Exercise or conversion : show line 5 in the form 10b5-1 Stock Option (right to buy) −4,250 216,870 D
Loading xslF345X05/form4-05302024_090558.xml…